First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- BMC cancer
- Publicado em
- 1 dez 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs
Yunwei Rao, Huan Rao, Yunkun Rao, Xinhai Wu, Huanxin Liu, Lianmin Zhu
Descritores MeSH
- Carcinoma, Non-Small-Cell Lung
- Immune Checkpoint Inhibitors
- Lung Neoplasms
- B7-H1 Antigen
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials, Phase III as Topic
- Progression-Free Survival
- Programmed Cell Death 1 Receptor
- Humans
- Neoplasm Staging
Veja também
Estudos relacionados
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis
- Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials
- Efficacy and safety of Programmed Death Ligand 1 inhibitors versus Programmed Death 1 inhibitors in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials